Fluorescence-Guided Surgery for Gliomas: Past, Present, and Future
Cancers · 30.05.2025 · 17 (11) · 1837
DOI: 10.3390/cancers17111837 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.05.2025. Verfasst von Benjamin Rodriguez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Glioblastoma (GBM) is the most common primary malignant central nervous system tumor, accounting for 50.9% of malignant CNS diagnoses and carrying a median survival of 15 months despite maximal standard therapy. High recurrence rates are driven by residual infiltrative tumor cells at the resection margin. Fluorescence-guided surgery (FGS) has emerged as a key innovation to improve intraoperative tumor visualization and maximize the extent of resection (EOR). This review examines the historical development, current clinical applications, and future directions of FGS in GBM surgery.
Methods
A comprehensive literature review was conducted, covering the evolution of fluorophores (fluorescein, indocyanine green [ICG], and 5-aminolevulinic acid [5-ALA]), visualization technologies (wide- and narrow-field modalities), therapeutic adjuncts (photodynamic and sonodynamic therapies), and clinical adoption patterns and outcomes.
Results
Early intraoperative fluorescence using fluorescein dates to 1947. ICG angiography has broad surgical utility, while 5-ALA received FDA approval in 2017, with phase III trials demonstrating gross total resection rates of 65% versus 36% with white-light surgery. Adjunct technologies—3D exoscopes, FGS-compatible loupes, and quantitative spectroscopy probes—enhance detection of residual tumor. Preliminary studies of intraoperative photodynamic and sonodynamic therapies show feasibility and potential survival benefits. Global adoption of 5-ALA FGS exceeds 75% among surveyed neurosurgeons.
Conclusions
FGS significantly improves EOR in GBM surgery, translating into better patient outcomes. Ongoing clinical trials and technological refinements—novel fluorophores, quantitative imaging, and therapeutic applications—promise to further optimize tumor visualization and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Sinai BioDesign, Department of Neurosurgery, Mount Sinai, New York, NY 10029, USA.
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
- Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
- Brain Tumor Nanotechnology Laboratory, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
- Center for Image-Guided Neurosurgery, Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
ORCID-Profile: Benjamin Rodriguez, Cole S Brown, Tirone Young, Tyree Williams, Varun Subramaniam
Zitieren
APA
Rodriguez, B., Brown, C. S., Colan, J. A., Zhang, J. Y., Huq, S., Rivera, D., Young, T., Williams, T., Subramaniam, V., & Hadjipanayis, C. (2025). Fluorescence-Guided Surgery for Gliomas: Past, Present, and Future. Cancers, 17(11), 1837. https://doi.org/10.3390/cancers17111837
Vancouver
Rodriguez B, Brown CS, Colan JA, Zhang JY, Huq S, Rivera D, et al. Fluorescence-Guided Surgery for Gliomas: Past, Present, and Future. Cancers. 2025;17(11):1837. doi:10.3390/cancers17111837
BibTeX
@article{Rodriguez2025,
author = {Rodriguez, Benjamin and Brown, Cole S and Colan, Jhair Alejandro and Zhang, Jack Yin and Huq, Sakibul and Rivera, Daniel and Young, Tirone and Williams, Tyree and Subramaniam, Varun and Hadjipanayis, Constantinos},
title = {Fluorescence-Guided Surgery for Gliomas: Past, Present, and Future},
journal = {Cancers},
year = {2025},
volume = {17},
number = {11},
pages = {1837},
doi = {10.3390/cancers17111837}
}
EUVIMED